NIKKEI 225
38,641.78 +8.76 (+0.02%) HANG SENG
17,998.16 -337.16 (-1.84%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,376.90 +7.90 (+0.33%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
50,966.12 -626.04 (-1.21%)
NVCR Jan 2025 17.500 call
| Previous close | 5.31 |
| Open | 5.50 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 17.50 |
| Expiry date | 2025-01-17 |
| Day's range | 5.31 - 5.50 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireMETIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
ROOT, Switzerland, June 03, 2024--Novocure (NASDAQ: NVCR) today announced the presentation of clinical data from the phase 3 METIS trial, which investigated the use of Tumor Treating Fields (TTFields) therapy in the treatment of brain metastases from non-small cell lung cancer (NSCLC). These data will be presented at the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Business WireTIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
ROOT, Switzerland, May 23, 2024--Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma (GBM) in Germany. The TIGER study enrolled 429 patients who used TTFields therapy between August 2017 and November 2019 and is the largest prospective, non-interventional study of the use of TTFields therapy in routine c
Insider MonkeyNovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript
NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript May 2, 2024 NovoCure Limited beats earnings expectations. Reported EPS is $-0.36134, expectations were $-0.43. NVCR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. […]
